novo nordisk glp-1 medications ad war leads to lawsuit by Nordisk, claiming Eli Lilly misleads Blockbuster GLP-1 Diabetes and Weight

Available as both subcutaneous (weekly) and oral (daily) formulations

Heres a recap of what weve covered: Orforglipron is a daily oral GLP-1 medication made by Eli Lilly that was approved by the FDA for weight loss and management under the brand name Foundayo in April 2026

236,237 GLP-1 RAs boost autophagic activity and eliminate misfolded proteins by inhibiting mTOR signaling and activating pathways such as AMPK, among others

Evidence shows that tirzepatide also confers better glycaemic control and bodyweight reductions than GLP-1 receptor agonists

This might be related to eating less or could be a direct effect of the medication

As you know on the Dr